0001104659-24-086127.txt : 20240806 0001104659-24-086127.hdr.sgml : 20240806 20240806085116 ACCESSION NUMBER: 0001104659-24-086127 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240806 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvectis Pharma, Inc. CENTRAL INDEX KEY: 0001875558 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 862405608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41264 FILM NUMBER: 241177265 BUSINESS ADDRESS: STREET 1: 1 BRIDGE PLAZA, SUITE 275 CITY: FORT LEE STATE: NJ ZIP: 07024 BUSINESS PHONE: 360-837-7232 MAIL ADDRESS: STREET 1: 1 BRIDGE PLAZA, SUITE 275 CITY: FORT LEE STATE: NJ ZIP: 07024 8-K 1 tm2420911d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 6, 2024

Nuvectis Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41264
(Commission File Number)

86-2405608
(IRS Employer Identification No.)

1 Bridge Plaza Suite 275

Fort Lee, NJ 07024

(Address of Principal Executive Offices)

(201) 614-3150

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Class	Trading Symbol(s)	Exchange Name
Common Stock	NVCT	Nasdaq Capital Market

¨	Written communications pursuant to Rule 425 under the Securities Act.

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

¨	Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02.

Results of Operations and Financial Condition.

On August 6, 2024, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report.

The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit Number		Description
99.1		Press release issued by Nuvectis Pharma, Inc., dated August 6, 2024.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nuvectis Pharma, Inc.
	(Registrant)

Date: August 6, 2024
	By:	/s/ Ron Bentsur
		Ron Bentsur
		Chairman, Chief Executive Officer and President

EX-99.1 2 tm2420911d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

August 6, 2024, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2024 and provided an update on recent business progress.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "During the second quarter we continued to advance our clinical trials for NXP800 and NXP900. For NXP800, the Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian cancer is continuing to enroll patients at approximately 15 clinical sites in the United States and United Kingdom and we remain on track to provide an update from this study during this fall. In addition, the Investigator-sponsored clinical trial in cholangiocarcinoma is also recruiting patients, and we plan to provide an update from this trial by the end of 2024. For NXP900, the dose escalation clinical trial is ongoing, and so far, three cohorts have been completed with no reports of dose limiting toxicities. We are continuing to plan the next steps in the development of NXP900, with particular interest in combination strategies with EGFR and ALK inhibitors in patients with advanced non-small cell lung cancer resistant to EGFR and ALK targeting drugs. Lastly, we continue to effectively manage our financial resources, which we believe can take us through the key milestones for both development programs”.

Second Quarter 2024 Financial Results

Cash, and cash equivalents were $18.1 million as of June 30, 2024 compared to $19.5 million as of March 31, 2024. The decrease of $1.4 million in the cash balance during the second quarter of 2024 is a result of the operating expenses for the quarter, partially offset by the utilization of the at-the market facility.

The Company's net loss was $4.4 million for the three months ended June 30, 2024, compared to $5.8 million for the three months ended June 30, 2023, a decrease in net loss of $1.4 million, rounded. Net loss for the second quarter of 2024 fiscal year included $1.3 million in non-cash stock-based compensation.

Research and development expenses, including non-cash stock-based compensation, were $2.9 million for the three months ended June 30, 2024, compared to $4.3 million for the three months ended June 30, 2023, a decrease of $1.4 million, rounded.

General and administrative expenses, including non-cash stock-based compensation, were $1.7 million for the three months ended June 30, 2024, compared to $1.5 million for the three months ended March 31, 2023, an increase of $0.2 million.

Interest income was $0.2 million for the three months ended June 30, 2024, compared to $0.1 million for the three months ended June 30, 2023, an increase of $0.1 million.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.

Forward Looking Statements

Certain statements in this presentation constitute “forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict and include statements regarding the preclinical data generated to date for NXP800 and NXP900, the Phase 1a data generated for NXP800 and the clinical expectations for the NXP800 Phase 1b study, including statements regarding NXP800's potential ability to become a therapeutic option for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma, cholangiocarcinoma, and potentially other cancer indications, and timing of and expectations for the Phase 1a study for NXP900. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2023 Form 10-K and our other public filings with the Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact

Ron Bentsur

Chairman, Chief Executive Officer and President

201-614-3151

rbentsur@nuvectis.com

Media Relations Contact

Christopher M. Calabrese

LifeSci Advisors

Tel: 917-680-5608

ccalabrese@lifesciadvisors.com

NUVECTIS PHARMA, INC.

BALANCE SHEET

(USD in thousands, except per share and share amounts)

		June 30,				December 31,
		2024				2023
Assets
CURRENT ASSETS
Cash and cash equivalents		$	18,116			$	19,126
Other current assets			182				59
TOTAL CURRENT ASSETS			18,298				19,185

TOTAL ASSETS		$	18,298			$	19,185

Liabilities and Stockholders’ Equity

CURRENT LIABILITIES
Accounts payables		$	1,846			$	2,771
Accrued liabilities			310				415
Employee compensation and benefits			3,614				3,798
TOTAL CURRENT LIABILITIES			5,770				6,984
TOTAL LIABILITIES			5,770				6,984

COMMITMENTS AND CONTINGENCIES,

STOCKHOLDERS’ EQUITY
Common Shares, $0.00001 par value – 60,000,000 shares authorized as of June 30, 2024, and December 31, 2023, 18,748,751, and 17,418,886 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively			*				*
Additional paid in capital			75,372				66,446
Accumulated deficit			(62,844	)			(54,245	)
TOTAL STOCKHOLDERS’ EQUITY			12,528				12,201
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	18,298			$	19,185

*

Represents an amount lower than $1,000 USD.

NUVECTIS PHARMA, INC.

STATEMENT OF OPERATIONS

(USD in thousands, except per share and share amounts)

		Three Months Ended June 30								Six Months Ended June 30
		2024				2023				2024				2023
OPERATING EXPENSES
Research and development		$	2,943			$	4,262			$	5,603			$	6,629
General and administrative			1,700				1,510				3,436				3,244

OPERATING LOSS			(4,643	)			(5,772	)			(9,039	)			(9,873	)
Finance income			215				64				440				116

NET LOSS		$	(4,428	)		$	(5,708	)		$	(8,599	)		$	(9,757	)

EX-101.SCH 3 nvct-20240806.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nvct-20240806_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nvct-20240806_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2420911d1_ex99-1img001.jpg GRAPHIC begin 644 tm2420911d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 06, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 06, 2024
Entity File Number	001-41264
Entity Registrant Name	Nuvectis Pharma, Inc.
Entity Central Index Key	0001875558
Entity Tax Identification Number	86-2405608
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1 Bridge Plaza Suite 275
Entity Address, City or Town	Fort Lee
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07024
City Area Code	201
Local Phone Number	614-3150
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	NVCT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &=&!ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !G1@99TX]$!^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^GJ(J';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E)]621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &=&!EE!KLLY900 !01 8 >&PO=V]R:W-H965T&UL MC9AO<^(V$,:_BL:=N6EG0FPY_+L4F"&$M.GE."YP=S/M](6P!=;$MEQ)#J2? MOBL#-KTS:]Z ;;R/?UJMGY48;*5ZT1'GANR2.-5#)S(FNW5='40\8?I:9CR% M7]92)8*SMQ2)10)3[60*5%\/73&]/;.[]B MXHZO@F_UR3&Q0UE)^6)/'L.AXUDB'O/ 6 D&7Z]\PN/8*@''/P=1IWRF#3P] M/JH_%(.'P:R8YA,9?Q.AB89.WR$A7[,\-L]R^SL_#*@ #&2LBT^RW=_;\1P2 MY-K(Y! ,!(E(]]]L=TC$20 ,M#[ /P3X!??^007E/3-L-%!R2Y2]&]3L03'4 M(AK@1&IG96$4_"H@SHPF\I6K@6M REYP@T/8W3[,/Q,VSC?7Q.M>$=_SV_\/ M=X&@Q/!+#+_0N\$PR%_CE38*)NKO.J*]0KM>P5;OKQGD4(N&+-\R7@>'A_=;'Q"(=@G11E7&0! 6% \QV]11 MX/%K%FN.<'1*CLYER9AS)61(IFE(H/AJ\X(K%654U%%3(75+MBZJ.$V-,&_D M0<2>8;84L;DC9C26VF<)U9_FI]3)-Y MQ,",KLAC&EPC?/V2KW\)WP2F4[$85$.^(Q_X6QTAKN1!VOJ]3J?31[#>EUCO M+\%:LAUY#(%-K$7 "AL_/ZFX8K_;\MM>I^MA>-2K;-.[!!!F0:I,JH+MBBP, MO 9$*C*1.204\BK#VLEN4+^?8I GWDXO@1R'(3BBOCH>D">XCWQ*Z\EP24KN ME @WG,QC]B\CBUS @/U>!^.MF@!%/?P'WHD]@VPNY3:M9<7EH&T;\L0QRZ-5 M Z"XA7_/5D[U7,E7D0;UR<0U9W]@:%5;H+BO?X\VE]K N_RGR,[7'Z[H]7 W MIE6KH+C#%U,XAO7B>11
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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nuvectis.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nvct-20240806.xsd nvct-20240806_lab.xml nvct-20240806_pre.xml tm2420911d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2420911d1_8k.htm": { "nsprefix": "NVCT", "nsuri": "http://nuvectis.com/20240806", "dts": { "schema": { "local": [ "nvct-20240806.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nvct-20240806_lab.xml" ] }, "presentationLink": { "local": [ "nvct-20240806_pre.xml" ] }, "inline": { "local": [ "tm2420911d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://nuvectis.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420911d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420911d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nuvectis.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-086127-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-086127-xbrl.zip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end XML 17 tm2420911d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001875558 2024-08-06 2024-08-06 iso4217:USD shares iso4217:USD shares false 0001875558 8-K 2024-08-06 Nuvectis Pharma, Inc. DE 001-41264 86-2405608 1 Bridge Plaza Suite 275 Fort Lee NJ 07024 201 614-3150 Common Stock NVCT NASDAQ false false false false true false